We believe that this episode has raised questions about the CDC's fundamental methodology. We urge you to subject this methodology to public exposure and critique in the course of a congressional investigation of the vaccine approval process. In particular, we urge you to subpoena the vaccine safety data and the internal reports about safety. We also call to your attention the fact that neither Donna Shalala nor Dr. Harold Margolis of the CDC's hepatitis division have responded to our queries about the safety testing of hepatitis B vaccine. This vaccine is once again being recommended for newborns now that a preparation without thimerosal is available.
Vaccines are a valuable weapon in our medical armamentarium.
Like all drugs, however, they may in certain patients and certain circumstances do more harm than good. Universal use of a vaccine is just as imprudent as universal use of any other pharmaceutical agent. Safety testing for a product that is used as broadly as a vaccine should be more rigorous than usual for pharmaceuticals, not less, particularly when recipients are children. Congress needs to meet its responsibility to oversee the agencies entrusted with making vaccine recommendations, as well as the process by which these are, all too often, converted into virtual mandates for universal use of a product that may harm many children.